Core Insights - The article highlights the recent financing and strategic developments of Zhonghui Pharmaceutical, including seed and angel round funding totaling nearly 50 million yuan [1][3] - Zhonghui Pharmaceutical is positioned as the first domestic company with independent intellectual property rights in hollow microneedle technology, aiming to break foreign monopolies in this field [5] Financing and Mergers - Zhonghui Pharmaceutical completed seed and angel round financing, with investments from Xincheng Investment, Aikang Chuangtan, Shaanxi Investment Growth Fund, and others [1] - The company also announced the acquisition and restructuring of Shanghai Lanwei Medical Technology Co., Ltd [3] Product and Technology Overview - The core product of Zhonghui Pharmaceutical is the hollow microneedle, which is designed for drug delivery, vaccine injection, aesthetic injection, and biosensing applications [6] - The hollow microneedles are characterized by their painlessness, minimally invasive nature, and high drug loading capacity, achieving international advanced standards [6] - The company is developing various products, including intradermal, suprachoroidal, and scalp injection hollow microneedles [6] Research and Development - Zhonghui Pharmaceutical is constructing the first automated biological tissue sample bank in Northwest China, which will support long-term preservation and scientific research of biological resources [8] - The company has launched its first gene-edited engineered stem cells with hair growth functions and is exploring applications in type 2 diabetes and ophthalmology using exosomes and gene-edited stem cells [8]